nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—breast cancer	0.257	1	CbGaD
Maraviroc—CYP3A4—Exemestane—breast cancer	0.0514	0.133	CbGbCtD
Maraviroc—CYP3A4—Letrozole—breast cancer	0.0437	0.113	CbGbCtD
Maraviroc—CYP3A4—Anastrozole—breast cancer	0.039	0.101	CbGbCtD
Maraviroc—CYP3A4—Toremifene—breast cancer	0.0356	0.0921	CbGbCtD
Maraviroc—CYP3A4—Fulvestrant—breast cancer	0.0331	0.0856	CbGbCtD
Maraviroc—CYP3A4—Thiotepa—breast cancer	0.0295	0.0763	CbGbCtD
Maraviroc—CYP3A4—Ixabepilone—breast cancer	0.027	0.0698	CbGbCtD
Maraviroc—CYP3A4—Lapatinib—breast cancer	0.026	0.0672	CbGbCtD
Maraviroc—CYP3A4—Raloxifene—breast cancer	0.0197	0.0509	CbGbCtD
Maraviroc—CYP3A4—Vinorelbine—breast cancer	0.0144	0.0373	CbGbCtD
Maraviroc—CYP3A4—Tamoxifen—breast cancer	0.013	0.0336	CbGbCtD
Maraviroc—CYP3A4—Mitoxantrone—breast cancer	0.0127	0.0328	CbGbCtD
Maraviroc—CYP3A4—Paclitaxel—breast cancer	0.0101	0.0262	CbGbCtD
Maraviroc—CYP3A4—Irinotecan—breast cancer	0.01	0.0258	CbGbCtD
Maraviroc—CYP3A4—Vinblastine—breast cancer	0.00889	0.023	CbGbCtD
Maraviroc—CYP3A4—Docetaxel—breast cancer	0.00733	0.0189	CbGbCtD
Maraviroc—CYP3A4—Doxorubicin—breast cancer	0.00546	0.0141	CbGbCtD
Maraviroc—CCR5—Signaling Pathways—PRL—breast cancer	5.35e-05	0.000453	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AGTR1—breast cancer	5.35e-05	0.000453	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ADAM10—breast cancer	5.27e-05	0.000447	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STK11—breast cancer	5.27e-05	0.000447	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—NCOA1—breast cancer	5.25e-05	0.000445	CbGpPWpGaD
Maraviroc—CCR5—Disease—CAV1—breast cancer	5.22e-05	0.000442	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PLG—breast cancer	5.21e-05	0.000442	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—breast cancer	5.17e-05	0.000438	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT2—breast cancer	5.15e-05	0.000437	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—breast cancer	5.14e-05	0.000436	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGF10—breast cancer	5.13e-05	0.000434	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA4—breast cancer	5.09e-05	0.000431	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—breast cancer	5.07e-05	0.00043	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTA4—breast cancer	5.02e-05	0.000425	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA2—breast cancer	4.96e-05	0.00042	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CD—breast cancer	4.95e-05	0.00042	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFA—breast cancer	4.95e-05	0.000419	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS2—breast cancer	4.91e-05	0.000416	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—SULT1A1—breast cancer	4.9e-05	0.000415	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GPX2—breast cancer	4.89e-05	0.000414	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFBR2—breast cancer	4.88e-05	0.000413	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOTCH1—breast cancer	4.86e-05	0.000412	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GPX4—breast cancer	4.83e-05	0.000409	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—SULT1A1—breast cancer	4.83e-05	0.000409	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ITPR1—breast cancer	4.8e-05	0.000407	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTA1—breast cancer	4.78e-05	0.000405	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB4—breast cancer	4.77e-05	0.000404	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP3—breast cancer	4.77e-05	0.000404	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT5A—breast cancer	4.77e-05	0.000404	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CB—breast cancer	4.75e-05	0.000403	CbGpPWpGaD
Maraviroc—CCR5—Disease—APC—breast cancer	4.75e-05	0.000403	CbGpPWpGaD
Maraviroc—CCR5—Disease—KIT—breast cancer	4.75e-05	0.000403	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—NAT2—breast cancer	4.73e-05	0.000401	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGF—breast cancer	4.7e-05	0.000398	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—NAT2—breast cancer	4.66e-05	0.000395	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SMAD4—breast cancer	4.62e-05	0.000391	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF1R—breast cancer	4.59e-05	0.000389	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCL8—breast cancer	4.57e-05	0.000387	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HES1—breast cancer	4.51e-05	0.000382	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NCOR1—breast cancer	4.48e-05	0.00038	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PLA2G4A—breast cancer	4.48e-05	0.00038	CbGpPWpGaD
Maraviroc—CCR5—Disease—BRAF—breast cancer	4.47e-05	0.000379	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGF1—breast cancer	4.43e-05	0.000376	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CSF2—breast cancer	4.43e-05	0.000376	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—RAF1—breast cancer	4.42e-05	0.000375	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NRG1—breast cancer	4.4e-05	0.000373	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—H2AFX—breast cancer	4.37e-05	0.00037	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2—breast cancer	4.37e-05	0.00037	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT2—breast cancer	4.35e-05	0.000368	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—E2F1—breast cancer	4.34e-05	0.000367	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CB—breast cancer	4.32e-05	0.000366	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CD—breast cancer	4.18e-05	0.000354	CbGpPWpGaD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—breast cancer	4.17e-05	0.000353	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SPP1—breast cancer	4.17e-05	0.000353	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCL8—breast cancer	4.15e-05	0.000352	CbGpPWpGaD
Maraviroc—CCR5—Disease—SERPINE1—breast cancer	4.13e-05	0.00035	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB3—breast cancer	4.12e-05	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGFR2—breast cancer	4.11e-05	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2—breast cancer	3.96e-05	0.000336	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TERT—breast cancer	3.95e-05	0.000335	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS3—breast cancer	3.94e-05	0.000334	CbGpPWpGaD
Maraviroc—Sinusitis—Epirubicin—breast cancer	3.94e-05	0.000166	CcSEcCtD
Maraviroc—Diarrhoea—Mitoxantrone—breast cancer	3.93e-05	0.000165	CcSEcCtD
Maraviroc—Diarrhoea—Irinotecan—breast cancer	3.93e-05	0.000165	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—MDM2—breast cancer	3.92e-05	0.000332	CbGpPWpGaD
Maraviroc—Agranulocytosis—Epirubicin—breast cancer	3.92e-05	0.000165	CcSEcCtD
Maraviroc—Pneumonia—Doxorubicin—breast cancer	3.91e-05	0.000164	CcSEcCtD
Maraviroc—Shock—Docetaxel—breast cancer	3.91e-05	0.000164	CcSEcCtD
Maraviroc—Nervous system disorder—Docetaxel—breast cancer	3.89e-05	0.000164	CcSEcCtD
Maraviroc—Pruritus—Fluorouracil—breast cancer	3.89e-05	0.000164	CcSEcCtD
Maraviroc—Infestation—Doxorubicin—breast cancer	3.89e-05	0.000164	CcSEcCtD
Maraviroc—Infestation NOS—Doxorubicin—breast cancer	3.89e-05	0.000164	CcSEcCtD
Maraviroc—Skin disorder—Docetaxel—breast cancer	3.86e-05	0.000162	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—MTR—breast cancer	3.86e-05	0.000327	CbGpPWpGaD
Maraviroc—Stevens-Johnson syndrome—Doxorubicin—breast cancer	3.85e-05	0.000162	CcSEcCtD
Maraviroc—Oedema—Capecitabine—breast cancer	3.84e-05	0.000162	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FGFR1—breast cancer	3.84e-05	0.000325	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Paclitaxel—breast cancer	3.83e-05	0.000161	CcSEcCtD
Maraviroc—Diarrhoea—Gemcitabine—breast cancer	3.83e-05	0.000161	CcSEcCtD
Maraviroc—Renal failure—Doxorubicin—breast cancer	3.82e-05	0.000161	CcSEcCtD
Maraviroc—Infection—Capecitabine—breast cancer	3.82e-05	0.000161	CcSEcCtD
Maraviroc—Erythema multiforme—Methotrexate—breast cancer	3.81e-05	0.00016	CcSEcCtD
Maraviroc—Neuropathy peripheral—Doxorubicin—breast cancer	3.81e-05	0.00016	CcSEcCtD
Maraviroc—Dizziness—Irinotecan—breast cancer	3.8e-05	0.00016	CcSEcCtD
Maraviroc—Stomatitis—Doxorubicin—breast cancer	3.79e-05	0.000159	CcSEcCtD
Maraviroc—Jaundice—Doxorubicin—breast cancer	3.79e-05	0.000159	CcSEcCtD
Maraviroc—Anorexia—Docetaxel—breast cancer	3.78e-05	0.000159	CcSEcCtD
Maraviroc—Shock—Capecitabine—breast cancer	3.78e-05	0.000159	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—HPGDS—breast cancer	3.78e-05	0.00032	CbGpPWpGaD
Maraviroc—Rhinitis—Epirubicin—breast cancer	3.78e-05	0.000159	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HIF1A—breast cancer	3.78e-05	0.00032	CbGpPWpGaD
Maraviroc—Conjunctivitis—Doxorubicin—breast cancer	3.78e-05	0.000159	CcSEcCtD
Maraviroc—Nervous system disorder—Capecitabine—breast cancer	3.77e-05	0.000159	CcSEcCtD
Maraviroc—Eye disorder—Methotrexate—breast cancer	3.76e-05	0.000158	CcSEcCtD
Maraviroc—Diarrhoea—Fluorouracil—breast cancer	3.76e-05	0.000158	CcSEcCtD
Maraviroc—CCR5—Disease—MDM2—breast cancer	3.74e-05	0.000317	CbGpPWpGaD
Maraviroc—Pharyngitis—Epirubicin—breast cancer	3.74e-05	0.000157	CcSEcCtD
Maraviroc—Cardiac disorder—Methotrexate—breast cancer	3.74e-05	0.000157	CcSEcCtD
Maraviroc—Skin disorder—Capecitabine—breast cancer	3.73e-05	0.000157	CcSEcCtD
Maraviroc—CCR5—Disease—RAF1—breast cancer	3.73e-05	0.000316	CbGpPWpGaD
Maraviroc—Urinary tract disorder—Epirubicin—breast cancer	3.72e-05	0.000157	CcSEcCtD
Maraviroc—Connective tissue disorder—Epirubicin—breast cancer	3.7e-05	0.000156	CcSEcCtD
Maraviroc—Abdominal pain—Paclitaxel—breast cancer	3.7e-05	0.000156	CcSEcCtD
Maraviroc—Body temperature increased—Paclitaxel—breast cancer	3.7e-05	0.000156	CcSEcCtD
Maraviroc—Urethral disorder—Epirubicin—breast cancer	3.7e-05	0.000156	CcSEcCtD
Maraviroc—CCR5—Disease—ERBB2—breast cancer	3.69e-05	0.000313	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LEP—breast cancer	3.69e-05	0.000312	CbGpPWpGaD
Maraviroc—Hepatobiliary disease—Doxorubicin—breast cancer	3.67e-05	0.000155	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTT1—breast cancer	3.67e-05	0.000311	CbGpPWpGaD
Maraviroc—Anorexia—Capecitabine—breast cancer	3.66e-05	0.000154	CcSEcCtD
Maraviroc—Angiopathy—Methotrexate—breast cancer	3.65e-05	0.000154	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CAV1—breast cancer	3.65e-05	0.00031	CbGpPWpGaD
Maraviroc—Vomiting—Irinotecan—breast cancer	3.65e-05	0.000154	CcSEcCtD
Maraviroc—Vomiting—Mitoxantrone—breast cancer	3.65e-05	0.000154	CcSEcCtD
Maraviroc—Sinusitis—Doxorubicin—breast cancer	3.65e-05	0.000153	CcSEcCtD
Maraviroc—CCR5—Disease—MTOR—breast cancer	3.64e-05	0.000309	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CB—breast cancer	3.64e-05	0.000309	CbGpPWpGaD
Maraviroc—Dizziness—Fluorouracil—breast cancer	3.64e-05	0.000153	CcSEcCtD
Maraviroc—CCR5—Disease—CD4—breast cancer	3.63e-05	0.000308	CbGpPWpGaD
Maraviroc—Mediastinal disorder—Methotrexate—breast cancer	3.63e-05	0.000153	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—breast cancer	3.63e-05	0.000153	CcSEcCtD
Maraviroc—Rash—Irinotecan—breast cancer	3.62e-05	0.000152	CcSEcCtD
Maraviroc—Rash—Mitoxantrone—breast cancer	3.62e-05	0.000152	CcSEcCtD
Maraviroc—Dermatitis—Irinotecan—breast cancer	3.62e-05	0.000152	CcSEcCtD
Maraviroc—Dermatitis—Mitoxantrone—breast cancer	3.62e-05	0.000152	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Docetaxel—breast cancer	3.62e-05	0.000152	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KDR—breast cancer	3.61e-05	0.000306	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—breast cancer	3.61e-05	0.000306	CbGpPWpGaD
Maraviroc—Headache—Irinotecan—breast cancer	3.6e-05	0.000151	CcSEcCtD
Maraviroc—Headache—Mitoxantrone—breast cancer	3.6e-05	0.000151	CcSEcCtD
Maraviroc—Insomnia—Docetaxel—breast cancer	3.59e-05	0.000151	CcSEcCtD
Maraviroc—Paraesthesia—Docetaxel—breast cancer	3.57e-05	0.00015	CcSEcCtD
Maraviroc—Erythema multiforme—Epirubicin—breast cancer	3.56e-05	0.00015	CcSEcCtD
Maraviroc—Alopecia—Methotrexate—breast cancer	3.56e-05	0.00015	CcSEcCtD
Maraviroc—Vomiting—Gemcitabine—breast cancer	3.56e-05	0.00015	CcSEcCtD
Maraviroc—Mental disorder—Methotrexate—breast cancer	3.53e-05	0.000149	CcSEcCtD
Maraviroc—Rash—Gemcitabine—breast cancer	3.53e-05	0.000148	CcSEcCtD
Maraviroc—Dermatitis—Gemcitabine—breast cancer	3.52e-05	0.000148	CcSEcCtD
Maraviroc—Eye disorder—Epirubicin—breast cancer	3.52e-05	0.000148	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ESR1—breast cancer	3.52e-05	0.000298	CbGpPWpGaD
Maraviroc—Malnutrition—Methotrexate—breast cancer	3.51e-05	0.000148	CcSEcCtD
Maraviroc—Erythema—Methotrexate—breast cancer	3.51e-05	0.000148	CcSEcCtD
Maraviroc—Headache—Gemcitabine—breast cancer	3.51e-05	0.000148	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Capecitabine—breast cancer	3.5e-05	0.000147	CcSEcCtD
Maraviroc—Cardiac disorder—Epirubicin—breast cancer	3.5e-05	0.000147	CcSEcCtD
Maraviroc—Vomiting—Fluorouracil—breast cancer	3.5e-05	0.000147	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—breast cancer	3.5e-05	0.000147	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—FN1—breast cancer	3.48e-05	0.000295	CbGpPWpGaD
Maraviroc—Insomnia—Capecitabine—breast cancer	3.48e-05	0.000146	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP17A1—breast cancer	3.47e-05	0.000294	CbGpPWpGaD
Maraviroc—Rash—Fluorouracil—breast cancer	3.47e-05	0.000146	CcSEcCtD
Maraviroc—Dermatitis—Fluorouracil—breast cancer	3.47e-05	0.000146	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—breast cancer	3.46e-05	0.000146	CcSEcCtD
Maraviroc—Paraesthesia—Capecitabine—breast cancer	3.45e-05	0.000145	CcSEcCtD
Maraviroc—Decreased appetite—Docetaxel—breast cancer	3.45e-05	0.000145	CcSEcCtD
Maraviroc—Hypersensitivity—Paclitaxel—breast cancer	3.45e-05	0.000145	CcSEcCtD
Maraviroc—Headache—Fluorouracil—breast cancer	3.45e-05	0.000145	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—breast cancer	3.44e-05	0.000145	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—PTGS1—breast cancer	3.44e-05	0.000291	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NFKBIA—breast cancer	3.44e-05	0.000291	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Docetaxel—breast cancer	3.43e-05	0.000144	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—breast cancer	3.43e-05	0.000144	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP17A1—breast cancer	3.42e-05	0.00029	CbGpPWpGaD
Maraviroc—Fatigue—Docetaxel—breast cancer	3.42e-05	0.000144	CcSEcCtD
Maraviroc—Angiopathy—Epirubicin—breast cancer	3.42e-05	0.000144	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—breast cancer	3.42e-05	0.000144	CcSEcCtD
Maraviroc—CCR5—Disease—CDKN1B—breast cancer	3.42e-05	0.00029	CbGpPWpGaD
Maraviroc—Nausea—Irinotecan—breast cancer	3.41e-05	0.000144	CcSEcCtD
Maraviroc—Nausea—Mitoxantrone—breast cancer	3.41e-05	0.000144	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NOTCH1—breast cancer	3.4e-05	0.000288	CbGpPWpGaD
Maraviroc—Mediastinal disorder—Epirubicin—breast cancer	3.4e-05	0.000143	CcSEcCtD
Maraviroc—Constipation—Docetaxel—breast cancer	3.4e-05	0.000143	CcSEcCtD
Maraviroc—Pain—Docetaxel—breast cancer	3.4e-05	0.000143	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP2D6—breast cancer	3.37e-05	0.000286	CbGpPWpGaD
Maraviroc—Asthenia—Paclitaxel—breast cancer	3.36e-05	0.000141	CcSEcCtD
Maraviroc—Decreased appetite—Capecitabine—breast cancer	3.34e-05	0.000141	CcSEcCtD
Maraviroc—Alopecia—Epirubicin—breast cancer	3.33e-05	0.00014	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—APC—breast cancer	3.33e-05	0.000282	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—breast cancer	3.33e-05	0.000282	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KIT—breast cancer	3.33e-05	0.000282	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP2D6—breast cancer	3.32e-05	0.000282	CbGpPWpGaD
Maraviroc—Nausea—Gemcitabine—breast cancer	3.32e-05	0.00014	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Capecitabine—breast cancer	3.32e-05	0.00014	CcSEcCtD
Maraviroc—Fatigue—Capecitabine—breast cancer	3.31e-05	0.000139	CcSEcCtD
Maraviroc—Pruritus—Paclitaxel—breast cancer	3.31e-05	0.000139	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—NCOA2—breast cancer	3.31e-05	0.00028	CbGpPWpGaD
Maraviroc—Mental disorder—Epirubicin—breast cancer	3.3e-05	0.000139	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—breast cancer	3.3e-05	0.000139	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EGF—breast cancer	3.29e-05	0.000279	CbGpPWpGaD
Maraviroc—Pain—Capecitabine—breast cancer	3.29e-05	0.000138	CcSEcCtD
Maraviroc—Constipation—Capecitabine—breast cancer	3.29e-05	0.000138	CcSEcCtD
Maraviroc—Malnutrition—Epirubicin—breast cancer	3.28e-05	0.000138	CcSEcCtD
Maraviroc—Erythema—Epirubicin—breast cancer	3.28e-05	0.000138	CcSEcCtD
Maraviroc—Nausea—Fluorouracil—breast cancer	3.27e-05	0.000138	CcSEcCtD
Maraviroc—Eye disorder—Doxorubicin—breast cancer	3.26e-05	0.000137	CcSEcCtD
Maraviroc—Gastrointestinal pain—Docetaxel—breast cancer	3.25e-05	0.000137	CcSEcCtD
Maraviroc—Anaemia—Methotrexate—breast cancer	3.24e-05	0.000136	CcSEcCtD
Maraviroc—Cardiac disorder—Doxorubicin—breast cancer	3.24e-05	0.000136	CcSEcCtD
Maraviroc—Flatulence—Epirubicin—breast cancer	3.23e-05	0.000136	CcSEcCtD
Maraviroc—CCR5—Disease—CTNNB1—breast cancer	3.23e-05	0.000274	CbGpPWpGaD
Maraviroc—Diarrhoea—Paclitaxel—breast cancer	3.21e-05	0.000135	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—MAPK3—breast cancer	3.19e-05	0.00027	CbGpPWpGaD
Maraviroc—Angiopathy—Doxorubicin—breast cancer	3.16e-05	0.000133	CcSEcCtD
Maraviroc—CCR5—Disease—CDKN1A—breast cancer	3.15e-05	0.000267	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—breast cancer	3.15e-05	0.000267	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Capecitabine—breast cancer	3.14e-05	0.000132	CcSEcCtD
Maraviroc—Mediastinal disorder—Doxorubicin—breast cancer	3.14e-05	0.000132	CcSEcCtD
Maraviroc—Abdominal pain—Docetaxel—breast cancer	3.14e-05	0.000132	CcSEcCtD
Maraviroc—Body temperature increased—Docetaxel—breast cancer	3.14e-05	0.000132	CcSEcCtD
Maraviroc—Leukopenia—Methotrexate—breast cancer	3.14e-05	0.000132	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—BRAF—breast cancer	3.13e-05	0.000265	CbGpPWpGaD
Maraviroc—Dizziness—Paclitaxel—breast cancer	3.1e-05	0.00013	CcSEcCtD
Maraviroc—Alopecia—Doxorubicin—breast cancer	3.08e-05	0.00013	CcSEcCtD
Maraviroc—Cough—Methotrexate—breast cancer	3.06e-05	0.000129	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—breast cancer	3.06e-05	0.000129	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IGF1—breast cancer	3.05e-05	0.000258	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT2—breast cancer	3.04e-05	0.000258	CbGpPWpGaD
Maraviroc—Abdominal pain—Capecitabine—breast cancer	3.04e-05	0.000128	CcSEcCtD
Maraviroc—Body temperature increased—Capecitabine—breast cancer	3.04e-05	0.000128	CcSEcCtD
Maraviroc—Convulsion—Methotrexate—breast cancer	3.04e-05	0.000128	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—breast cancer	3.04e-05	0.000128	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—breast cancer	3.04e-05	0.000128	CcSEcCtD
Maraviroc—Anaemia—Epirubicin—breast cancer	3.03e-05	0.000128	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—EGFR—breast cancer	3.03e-05	0.000257	CbGpPWpGaD
Maraviroc—Flatulence—Doxorubicin—breast cancer	2.99e-05	0.000126	CcSEcCtD
Maraviroc—Myalgia—Methotrexate—breast cancer	2.99e-05	0.000126	CcSEcCtD
Maraviroc—Vomiting—Paclitaxel—breast cancer	2.98e-05	0.000125	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.96e-05	0.000125	CcSEcCtD
Maraviroc—Rash—Paclitaxel—breast cancer	2.95e-05	0.000124	CcSEcCtD
Maraviroc—Dermatitis—Paclitaxel—breast cancer	2.95e-05	0.000124	CcSEcCtD
Maraviroc—Discomfort—Methotrexate—breast cancer	2.95e-05	0.000124	CcSEcCtD
Maraviroc—Syncope—Epirubicin—breast cancer	2.94e-05	0.000124	CcSEcCtD
Maraviroc—Leukopenia—Epirubicin—breast cancer	2.94e-05	0.000124	CcSEcCtD
Maraviroc—Headache—Paclitaxel—breast cancer	2.93e-05	0.000124	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PIK3CD—breast cancer	2.93e-05	0.000248	CbGpPWpGaD
Maraviroc—Hypersensitivity—Docetaxel—breast cancer	2.93e-05	0.000123	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP1B1—breast cancer	2.92e-05	0.000248	CbGpPWpGaD
Maraviroc—CCR5—Disease—SRC—breast cancer	2.92e-05	0.000247	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—breast cancer	2.9e-05	0.000246	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SERPINE1—breast cancer	2.89e-05	0.000245	CbGpPWpGaD
Maraviroc—Loss of consciousness—Epirubicin—breast cancer	2.88e-05	0.000121	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1B1—breast cancer	2.88e-05	0.000244	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—KRAS—breast cancer	2.86e-05	0.000243	CbGpPWpGaD
Maraviroc—Cough—Epirubicin—breast cancer	2.86e-05	0.000121	CcSEcCtD
Maraviroc—Asthenia—Docetaxel—breast cancer	2.85e-05	0.00012	CcSEcCtD
Maraviroc—Convulsion—Epirubicin—breast cancer	2.84e-05	0.00012	CcSEcCtD
Maraviroc—Infection—Methotrexate—breast cancer	2.84e-05	0.00012	CcSEcCtD
Maraviroc—Hypersensitivity—Capecitabine—breast cancer	2.83e-05	0.000119	CcSEcCtD
Maraviroc—CCR5—Disease—STAT3—breast cancer	2.81e-05	0.000238	CbGpPWpGaD
Maraviroc—Pruritus—Docetaxel—breast cancer	2.81e-05	0.000118	CcSEcCtD
Maraviroc—Nervous system disorder—Methotrexate—breast cancer	2.81e-05	0.000118	CcSEcCtD
Maraviroc—Anaemia—Doxorubicin—breast cancer	2.81e-05	0.000118	CcSEcCtD
Maraviroc—Myalgia—Epirubicin—breast cancer	2.79e-05	0.000118	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—NCOA1—breast cancer	2.79e-05	0.000236	CbGpPWpGaD
Maraviroc—Anxiety—Epirubicin—breast cancer	2.78e-05	0.000117	CcSEcCtD
Maraviroc—Nausea—Paclitaxel—breast cancer	2.78e-05	0.000117	CcSEcCtD
Maraviroc—Skin disorder—Methotrexate—breast cancer	2.78e-05	0.000117	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.77e-05	0.000117	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NOS3—breast cancer	2.76e-05	0.000234	CbGpPWpGaD
Maraviroc—Discomfort—Epirubicin—breast cancer	2.76e-05	0.000116	CcSEcCtD
Maraviroc—Asthenia—Capecitabine—breast cancer	2.76e-05	0.000116	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—CYP19A1—breast cancer	2.75e-05	0.000233	CbGpPWpGaD
Maraviroc—Anorexia—Methotrexate—breast cancer	2.73e-05	0.000115	CcSEcCtD
Maraviroc—Syncope—Doxorubicin—breast cancer	2.72e-05	0.000115	CcSEcCtD
Maraviroc—Pruritus—Capecitabine—breast cancer	2.72e-05	0.000114	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—breast cancer	2.72e-05	0.000114	CcSEcCtD
Maraviroc—Diarrhoea—Docetaxel—breast cancer	2.72e-05	0.000114	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP19A1—breast cancer	2.71e-05	0.00023	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAPK3—breast cancer	2.69e-05	0.000228	CbGpPWpGaD
Maraviroc—Oedema—Epirubicin—breast cancer	2.68e-05	0.000113	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—breast cancer	2.67e-05	0.000112	CcSEcCtD
Maraviroc—Infection—Epirubicin—breast cancer	2.66e-05	0.000112	CcSEcCtD
Maraviroc—Cough—Doxorubicin—breast cancer	2.65e-05	0.000112	CcSEcCtD
Maraviroc—Shock—Epirubicin—breast cancer	2.63e-05	0.000111	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—breast cancer	2.63e-05	0.000223	CbGpPWpGaD
Maraviroc—Convulsion—Doxorubicin—breast cancer	2.63e-05	0.000111	CcSEcCtD
Maraviroc—Diarrhoea—Capecitabine—breast cancer	2.63e-05	0.000111	CcSEcCtD
Maraviroc—Nervous system disorder—Epirubicin—breast cancer	2.63e-05	0.000111	CcSEcCtD
Maraviroc—Dizziness—Docetaxel—breast cancer	2.63e-05	0.00011	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MDM2—breast cancer	2.62e-05	0.000222	CbGpPWpGaD
Maraviroc—CCR5—Disease—MYC—breast cancer	2.61e-05	0.000222	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RAF1—breast cancer	2.61e-05	0.000221	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—breast cancer	2.61e-05	0.000221	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Methotrexate—breast cancer	2.61e-05	0.00011	CcSEcCtD
Maraviroc—Skin disorder—Epirubicin—breast cancer	2.6e-05	0.000109	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RELA—breast cancer	2.6e-05	0.00022	CbGpPWpGaD
Maraviroc—Insomnia—Methotrexate—breast cancer	2.59e-05	0.000109	CcSEcCtD
Maraviroc—Myalgia—Doxorubicin—breast cancer	2.58e-05	0.000109	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—ERBB2—breast cancer	2.58e-05	0.000219	CbGpPWpGaD
Maraviroc—Anxiety—Doxorubicin—breast cancer	2.58e-05	0.000108	CcSEcCtD
Maraviroc—Paraesthesia—Methotrexate—breast cancer	2.57e-05	0.000108	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.57e-05	0.000108	CcSEcCtD
Maraviroc—CCR5—Disease—EGFR—breast cancer	2.56e-05	0.000217	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—COMT—breast cancer	2.55e-05	0.000216	CbGpPWpGaD
Maraviroc—Discomfort—Doxorubicin—breast cancer	2.55e-05	0.000107	CcSEcCtD
Maraviroc—Anorexia—Epirubicin—breast cancer	2.55e-05	0.000107	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PIK3CB—breast cancer	2.55e-05	0.000216	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MTOR—breast cancer	2.55e-05	0.000216	CbGpPWpGaD
Maraviroc—Dizziness—Capecitabine—breast cancer	2.54e-05	0.000107	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—breast cancer	2.54e-05	0.000215	CbGpPWpGaD
Maraviroc—Vomiting—Docetaxel—breast cancer	2.52e-05	0.000106	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—COMT—breast cancer	2.52e-05	0.000213	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—breast cancer	2.51e-05	0.000212	CbGpPWpGaD
Maraviroc—Rash—Docetaxel—breast cancer	2.5e-05	0.000105	CcSEcCtD
Maraviroc—Dermatitis—Docetaxel—breast cancer	2.5e-05	0.000105	CcSEcCtD
Maraviroc—Decreased appetite—Methotrexate—breast cancer	2.49e-05	0.000105	CcSEcCtD
Maraviroc—Headache—Docetaxel—breast cancer	2.49e-05	0.000105	CcSEcCtD
Maraviroc—Oedema—Doxorubicin—breast cancer	2.48e-05	0.000104	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Methotrexate—breast cancer	2.47e-05	0.000104	CcSEcCtD
Maraviroc—Fatigue—Methotrexate—breast cancer	2.47e-05	0.000104	CcSEcCtD
Maraviroc—Infection—Doxorubicin—breast cancer	2.46e-05	0.000104	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CXCL8—breast cancer	2.45e-05	0.000208	CbGpPWpGaD
Maraviroc—Pain—Methotrexate—breast cancer	2.45e-05	0.000103	CcSEcCtD
Maraviroc—Vomiting—Capecitabine—breast cancer	2.44e-05	0.000103	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Epirubicin—breast cancer	2.44e-05	0.000103	CcSEcCtD
Maraviroc—Shock—Doxorubicin—breast cancer	2.44e-05	0.000103	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—HRAS—breast cancer	2.43e-05	0.000206	CbGpPWpGaD
Maraviroc—Nervous system disorder—Doxorubicin—breast cancer	2.43e-05	0.000102	CcSEcCtD
Maraviroc—Rash—Capecitabine—breast cancer	2.42e-05	0.000102	CcSEcCtD
Maraviroc—Insomnia—Epirubicin—breast cancer	2.42e-05	0.000102	CcSEcCtD
Maraviroc—Dermatitis—Capecitabine—breast cancer	2.42e-05	0.000102	CcSEcCtD
Maraviroc—CCR5—Disease—KRAS—breast cancer	2.42e-05	0.000205	CbGpPWpGaD
Maraviroc—Headache—Capecitabine—breast cancer	2.41e-05	0.000101	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—breast cancer	2.41e-05	0.000101	CcSEcCtD
Maraviroc—Paraesthesia—Epirubicin—breast cancer	2.4e-05	0.000101	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CDKN1B—breast cancer	2.39e-05	0.000203	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—breast cancer	2.37e-05	0.000201	CbGpPWpGaD
Maraviroc—Anorexia—Doxorubicin—breast cancer	2.36e-05	9.94e-05	CcSEcCtD
Maraviroc—Nausea—Docetaxel—breast cancer	2.36e-05	9.93e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CASP3—breast cancer	2.35e-05	0.000199	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—breast cancer	2.34e-05	0.000198	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Methotrexate—breast cancer	2.34e-05	9.85e-05	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—breast cancer	2.34e-05	0.000198	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—breast cancer	2.33e-05	0.000197	CbGpPWpGaD
Maraviroc—Decreased appetite—Epirubicin—breast cancer	2.33e-05	9.8e-05	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Epirubicin—breast cancer	2.31e-05	9.73e-05	CcSEcCtD
Maraviroc—Fatigue—Epirubicin—breast cancer	2.31e-05	9.72e-05	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—breast cancer	2.3e-05	0.000195	CbGpPWpGaD
Maraviroc—Constipation—Epirubicin—breast cancer	2.29e-05	9.64e-05	CcSEcCtD
Maraviroc—Pain—Epirubicin—breast cancer	2.29e-05	9.64e-05	CcSEcCtD
Maraviroc—Nausea—Capecitabine—breast cancer	2.28e-05	9.61e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCND1—breast cancer	2.28e-05	0.000193	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JUN—breast cancer	2.28e-05	0.000193	CbGpPWpGaD
Maraviroc—Body temperature increased—Methotrexate—breast cancer	2.26e-05	9.52e-05	CcSEcCtD
Maraviroc—Abdominal pain—Methotrexate—breast cancer	2.26e-05	9.52e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CTNNB1—breast cancer	2.26e-05	0.000192	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.26e-05	9.5e-05	CcSEcCtD
Maraviroc—Insomnia—Doxorubicin—breast cancer	2.24e-05	9.43e-05	CcSEcCtD
Maraviroc—Paraesthesia—Doxorubicin—breast cancer	2.23e-05	9.36e-05	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CA—breast cancer	2.22e-05	0.000188	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—breast cancer	2.22e-05	0.000188	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1A1—breast cancer	2.21e-05	0.000188	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1A—breast cancer	2.21e-05	0.000187	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTEN—breast cancer	2.2e-05	0.000187	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Epirubicin—breast cancer	2.19e-05	9.22e-05	CcSEcCtD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1A1—breast cancer	2.18e-05	0.000185	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK8—breast cancer	2.16e-05	0.000183	CbGpPWpGaD
Maraviroc—Decreased appetite—Doxorubicin—breast cancer	2.15e-05	9.07e-05	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AKT1—breast cancer	2.15e-05	0.000182	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Doxorubicin—breast cancer	2.14e-05	9e-05	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—breast cancer	2.14e-05	8.99e-05	CcSEcCtD
Maraviroc—Pain—Doxorubicin—breast cancer	2.12e-05	8.92e-05	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—breast cancer	2.12e-05	8.92e-05	CcSEcCtD
Maraviroc—Abdominal pain—Epirubicin—breast cancer	2.12e-05	8.91e-05	CcSEcCtD
Maraviroc—Body temperature increased—Epirubicin—breast cancer	2.12e-05	8.91e-05	CcSEcCtD
Maraviroc—Hypersensitivity—Methotrexate—breast cancer	2.11e-05	8.87e-05	CcSEcCtD
Maraviroc—CCR5—Disease—HRAS—breast cancer	2.05e-05	0.000174	CbGpPWpGaD
Maraviroc—Asthenia—Methotrexate—breast cancer	2.05e-05	8.64e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SRC—breast cancer	2.04e-05	0.000173	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Doxorubicin—breast cancer	2.03e-05	8.53e-05	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—breast cancer	2.02e-05	8.52e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—VEGFA—breast cancer	1.99e-05	0.000169	CbGpPWpGaD
Maraviroc—Hypersensitivity—Epirubicin—breast cancer	1.97e-05	8.3e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—STAT3—breast cancer	1.97e-05	0.000167	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—breast cancer	1.97e-05	0.000167	CbGpPWpGaD
Maraviroc—Body temperature increased—Doxorubicin—breast cancer	1.96e-05	8.24e-05	CcSEcCtD
Maraviroc—Abdominal pain—Doxorubicin—breast cancer	1.96e-05	8.24e-05	CcSEcCtD
Maraviroc—Diarrhoea—Methotrexate—breast cancer	1.96e-05	8.24e-05	CcSEcCtD
Maraviroc—Asthenia—Epirubicin—breast cancer	1.92e-05	8.09e-05	CcSEcCtD
Maraviroc—Pruritus—Epirubicin—breast cancer	1.89e-05	7.97e-05	CcSEcCtD
Maraviroc—Dizziness—Methotrexate—breast cancer	1.89e-05	7.96e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MAPK3—breast cancer	1.88e-05	0.00016	CbGpPWpGaD
Maraviroc—Diarrhoea—Epirubicin—breast cancer	1.83e-05	7.71e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MYC—breast cancer	1.83e-05	0.000155	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—breast cancer	1.83e-05	0.000155	CbGpPWpGaD
Maraviroc—Hypersensitivity—Doxorubicin—breast cancer	1.83e-05	7.68e-05	CcSEcCtD
Maraviroc—Vomiting—Methotrexate—breast cancer	1.82e-05	7.66e-05	CcSEcCtD
Maraviroc—CCR5—Disease—AKT1—breast cancer	1.81e-05	0.000154	CbGpPWpGaD
Maraviroc—Rash—Methotrexate—breast cancer	1.8e-05	7.59e-05	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—breast cancer	1.8e-05	7.59e-05	CcSEcCtD
Maraviroc—Headache—Methotrexate—breast cancer	1.79e-05	7.54e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EGFR—breast cancer	1.79e-05	0.000152	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SYNJ2—breast cancer	1.78e-05	0.000151	CbGpPWpGaD
Maraviroc—Asthenia—Doxorubicin—breast cancer	1.78e-05	7.48e-05	CcSEcCtD
Maraviroc—Dizziness—Epirubicin—breast cancer	1.77e-05	7.45e-05	CcSEcCtD
Maraviroc—Pruritus—Doxorubicin—breast cancer	1.75e-05	7.38e-05	CcSEcCtD
Maraviroc—Vomiting—Epirubicin—breast cancer	1.7e-05	7.17e-05	CcSEcCtD
Maraviroc—Nausea—Methotrexate—breast cancer	1.7e-05	7.15e-05	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—breast cancer	1.7e-05	7.14e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KRAS—breast cancer	1.69e-05	0.000143	CbGpPWpGaD
Maraviroc—Rash—Epirubicin—breast cancer	1.69e-05	7.11e-05	CcSEcCtD
Maraviroc—Dermatitis—Epirubicin—breast cancer	1.69e-05	7.1e-05	CcSEcCtD
Maraviroc—Headache—Epirubicin—breast cancer	1.68e-05	7.06e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—NDUFS3—breast cancer	1.66e-05	0.00014	CbGpPWpGaD
Maraviroc—Dizziness—Doxorubicin—breast cancer	1.64e-05	6.9e-05	CcSEcCtD
Maraviroc—Nausea—Epirubicin—breast cancer	1.59e-05	6.69e-05	CcSEcCtD
Maraviroc—Vomiting—Doxorubicin—breast cancer	1.58e-05	6.63e-05	CcSEcCtD
Maraviroc—Rash—Doxorubicin—breast cancer	1.56e-05	6.58e-05	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—breast cancer	1.56e-05	6.57e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—CHST9—breast cancer	1.56e-05	0.000132	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—breast cancer	1.55e-05	0.000132	CbGpPWpGaD
Maraviroc—Headache—Doxorubicin—breast cancer	1.55e-05	6.53e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TP53—breast cancer	1.5e-05	0.000127	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—COX11—breast cancer	1.48e-05	0.000125	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—breast cancer	1.47e-05	6.19e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HRAS—breast cancer	1.44e-05	0.000122	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—breast cancer	1.38e-05	0.000117	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CDA—breast cancer	1.35e-05	0.000114	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SHMT1—breast cancer	1.35e-05	0.000114	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLCO1B1—breast cancer	1.3e-05	0.00011	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC2A5—breast cancer	1.3e-05	0.00011	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—breast cancer	1.27e-05	0.000108	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—APRT—breast cancer	1.26e-05	0.000106	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ESRRA—breast cancer	1.18e-05	0.0001	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ANGPTL4—breast cancer	1.18e-05	0.0001	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HADHB—breast cancer	1.12e-05	9.48e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPI—breast cancer	1.12e-05	9.48e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDH1A1—breast cancer	1.07e-05	9.04e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDH7A1—breast cancer	1.07e-05	9.04e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UMPS—breast cancer	1.02e-05	8.67e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NME1—breast cancer	1.02e-05	8.67e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ADSL—breast cancer	1.02e-05	8.67e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—FHL2—breast cancer	1.02e-05	8.67e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PHGDH—breast cancer	1.02e-05	8.67e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPSE—breast cancer	1e-05	8.5e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BRIP1—breast cancer	1e-05	8.5e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LDHB—breast cancer	1e-05	8.5e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMMR—breast cancer	9.51e-06	8.06e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA3—breast cancer	9.51e-06	8.06e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCC1—breast cancer	9.51e-06	8.06e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARGC1B—breast cancer	9.21e-06	7.81e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA4—breast cancer	8.7e-06	7.37e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CA9—breast cancer	8.7e-06	7.37e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPX2—breast cancer	8.48e-06	7.18e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA2—breast cancer	8.48e-06	7.18e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SULT1A1—breast cancer	8.37e-06	7.1e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPX4—breast cancer	8.37e-06	7.1e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—IDH1—breast cancer	8.18e-06	6.93e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTA1—breast cancer	8.18e-06	6.93e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NAT2—breast cancer	8.09e-06	6.85e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—DPYD—breast cancer	7.09e-06	6.01e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MED12—breast cancer	7.09e-06	6.01e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALDOA—breast cancer	6.98e-06	5.92e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA3—breast cancer	6.78e-06	5.74e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC2A2—breast cancer	6.73e-06	5.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCG2—breast cancer	6.59e-06	5.59e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CPT1A—breast cancer	6.59e-06	5.59e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTR—breast cancer	6.59e-06	5.59e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPGDS—breast cancer	6.47e-06	5.48e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HBA1—breast cancer	6.43e-06	5.45e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTT1—breast cancer	6.27e-06	5.31e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ACHE—breast cancer	6.27e-06	5.31e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP17A1—breast cancer	5.94e-06	5.03e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ENO1—breast cancer	5.88e-06	4.98e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS1—breast cancer	5.88e-06	4.98e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP2D6—breast cancer	5.76e-06	4.88e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA2—breast cancer	5.66e-06	4.79e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—FASN—breast cancer	5.49e-06	4.65e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BCHE—breast cancer	5.46e-06	4.63e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A5—breast cancer	5.4e-06	4.57e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NQO1—breast cancer	5.21e-06	4.42e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC2A1—breast cancer	5.21e-06	4.42e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1B1—breast cancer	5e-06	4.23e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSP90AA1—breast cancer	4.9e-06	4.15e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA1—breast cancer	4.77e-06	4.04e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP19A1—breast cancer	4.7e-06	3.98e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—STK11—breast cancer	4.7e-06	3.98e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—COMT—breast cancer	4.37e-06	3.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—breast cancer	4.35e-06	3.68e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMOX1—breast cancer	4.29e-06	3.63e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ITPR1—breast cancer	4.28e-06	3.62e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCB1—breast cancer	4.12e-06	3.49e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TYMS—breast cancer	4.04e-06	3.42e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—breast cancer	3.99e-06	3.39e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLA2G4A—breast cancer	3.99e-06	3.39e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOR1—breast cancer	3.99e-06	3.39e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPX1—breast cancer	3.83e-06	3.24e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1A1—breast cancer	3.79e-06	3.21e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ERCC2—breast cancer	3.76e-06	3.18e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTHFR—breast cancer	3.53e-06	2.99e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CAV1—breast cancer	3.26e-06	2.76e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—breast cancer	2.97e-06	2.51e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CD—breast cancer	2.61e-06	2.21e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—breast cancer	2.57e-06	2.18e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NOS3—breast cancer	2.46e-06	2.09e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CB—breast cancer	2.27e-06	1.93e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—breast cancer	2.25e-06	1.91e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—breast cancer	1.96e-06	1.66e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—breast cancer	1.39e-06	1.17e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—breast cancer	1.13e-06	9.59e-06	CbGpPWpGaD
